Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Liabilities and Shareholders Equity (2021 - 2025)

Historic Liabilities and Shareholders Equity for Lyra Therapeutics (LYRA) over the last 5 years, with Q3 2025 value amounting to $43.7 million.

  • Lyra Therapeutics' Liabilities and Shareholders Equity fell 4450.07% to $43.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $218.9 million, marking a year-over-year decrease of 5213.97%. This contributed to the annual value of $66.3 million for FY2024, which is 5347.41% down from last year.
  • Lyra Therapeutics' Liabilities and Shareholders Equity amounted to $43.7 million in Q3 2025, which was down 4450.07% from $52.6 million recorded in Q2 2025.
  • In the past 5 years, Lyra Therapeutics' Liabilities and Shareholders Equity registered a high of $142.6 million during Q4 2023, and its lowest value of $43.7 million during Q3 2025.
  • In the last 5 years, Lyra Therapeutics' Liabilities and Shareholders Equity had a median value of $78.8 million in 2024 and averaged $89.2 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first skyrocketed by 10042.65% in 2022, then tumbled by 6020.83% in 2025.
  • Quarter analysis of 5 years shows Lyra Therapeutics' Liabilities and Shareholders Equity stood at $54.9 million in 2021, then skyrocketed by 100.43% to $110.0 million in 2022, then grew by 29.67% to $142.6 million in 2023, then plummeted by 53.47% to $66.3 million in 2024, then tumbled by 34.12% to $43.7 million in 2025.
  • Its last three reported values are $43.7 million in Q3 2025, $52.6 million for Q2 2025, and $56.3 million during Q1 2025.